Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Classical hematology 1

Conditions

Neoplasms 3Arthritis, Rheumatoid 3Graft vs Host Disease 2Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia 1Hematologic Neoplasms 1Arthritis 1Anemia, Refractory 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Neoplasms × Abatacept × Clear all
NCT01743131 2025-12-11

Abatacept as GVHD Prophylaxis Phase 2

Boston Children's Hospital

Phase 2 Completed
186 enrolled 14 charts 1 FDA

Graft vs Host Disease, Neoplasms

NCT03680092 2025-10-02

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

University of California, San Diego

Phase 2 Completed
43 enrolled 10 charts
Other hematologic neoplasm

Graft vs Host Disease, Neoplasms, Hematologic Neoplasms

NCT01012492 2019-11-21

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

Boston Children's Hospital

Phase 2 Completed
11 enrolled 10 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Leukemia, Myelodysplastic Syndromes, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡